Patents by Inventor Yasuharu Nishimura
Yasuharu Nishimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150191516Abstract: Isolated LY6K-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can be promiscuously bind to MHC class II molecules and induce LY6K-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.Type: ApplicationFiled: July 9, 2013Publication date: July 9, 2015Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
-
Patent number: 9073968Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.Type: GrantFiled: September 25, 2013Date of Patent: July 7, 2015Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Yasuharu Nishimura, Kazunori Yokomine, Takuya Tsunoda, Yusuke Nakamura
-
Publication number: 20150017193Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.Type: ApplicationFiled: September 29, 2014Publication date: January 15, 2015Inventors: Yasuharu NISHIMURA, Katsunori IMAI, Yusuke NAKAMURA, Takuya TSUNODA
-
Patent number: 8883966Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.Type: GrantFiled: October 15, 2009Date of Patent: November 11, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
-
Publication number: 20140023672Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.Type: ApplicationFiled: September 25, 2013Publication date: January 23, 2014Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yasuharu Nishimura, Kazunori Yokomine, Takuya Tsunoda, Yusuke Nakamura
-
Patent number: 8598125Abstract: The present invention provides the peptide of (A) or (B) below, and methods of using the peptide: (A) a peptide including the amino acid sequence of SEQ ID NO: 1 or 2, (B) a peptide which includes the amino acid sequence of SEQ ID NO: 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows killer T cell-inducing activity.Type: GrantFiled: June 13, 2008Date of Patent: December 3, 2013Assignee: Onco Therapy Science, Inc.Inventors: Yasuharu Nishimura, Michiko Harao, Takuya Tsunoda, Yusuke Nakamura
-
Patent number: 8586547Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer.Type: GrantFiled: May 25, 2010Date of Patent: November 19, 2013Assignee: Oncotherapy Science, Inc.Inventors: Yasuharu Nishimura, Yusuke Tomita, Yusuke Nakamura, Takuya Tsunoda
-
Publication number: 20130288363Abstract: It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.Type: ApplicationFiled: May 23, 2013Publication date: October 31, 2013Inventors: Yasuharu NISHIMURA, Yoshiaki IKUTA, Shuichi NAKATSURU
-
Patent number: 8569244Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.Type: GrantFiled: August 12, 2008Date of Patent: October 29, 2013Assignee: OncoTherapy Science, Inc.Inventors: Yasuharu Nishimura, Kazunori Yokomine, Takuya Tsunoda, Yusuke Nakamura
-
Patent number: 8535942Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.Type: GrantFiled: September 23, 2011Date of Patent: September 17, 2013Assignee: Oncotherapy Science, Inc.Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Hiroyuki Komori
-
Patent number: 8470968Abstract: It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.Type: GrantFiled: September 23, 2011Date of Patent: June 25, 2013Assignee: Onco Therapy Science, Inc.Inventors: Yasuharu Nishimura, Yoshiaki Ikuta, Shuichi Nakatsuru
-
Patent number: 8455444Abstract: The present invention provides a peptide of the following (A) or (B): (A) a peptide including an amino acid sequence of SEQ ID NO: 1 or 2; (B) a peptide including an amino acid sequence of SEQ ID NO 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide has an activity to induce killer T cells.Type: GrantFiled: June 5, 2008Date of Patent: June 4, 2013Assignee: Oncotherapy Science, Inc.Inventors: Yasuharu Nishimura, Katsunori Imai, Takuya Tsunoda, Yusuke Nakamura
-
Publication number: 20120308590Abstract: Oligopeptides having cytotoxic T cell inducibility and suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. Notable examples include oligopeptides having the amino acid sequence of SEQ ID NO: 1, 3, 5 or 6, wherein 1, 2, or several amino acids are optionally substituted, deleted, inserted or added so long as they retain the cytotoxic T cell inducibility of the original oligopeptides. Pharmaceutical formulations or “drugs” related to such oligopeptides suitable for treating or preventing cancers or tumors, as well as the post-operative recurrence thereof, are also described.Type: ApplicationFiled: November 30, 2010Publication date: December 6, 2012Applicant: OncoTherapy Science, Inc.Inventors: Yasuharu Nishimura, Michiko Harao, Yusuke Tomita, Yusuke Nakamura, Takuya Tsunoda
-
Publication number: 20120164163Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer.Type: ApplicationFiled: May 25, 2010Publication date: June 28, 2012Inventors: Yasuharu Nishimura, Yusuke Tomita, Yusuke Nakamura, Takuya Tsunoda
-
Publication number: 20120115221Abstract: It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.Type: ApplicationFiled: September 23, 2011Publication date: May 10, 2012Applicant: ONCO THERAPY SCIENCE, INC.Inventors: Yasuharu NISHIMURA, Yoshiaki IKUTA, Shuichi NAKATSURU
-
Publication number: 20120040452Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.Type: ApplicationFiled: September 23, 2011Publication date: February 16, 2012Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yasuharu NISHIMURA, Tetsuya NAKATSURA, Hiroyuki KOMORI
-
Patent number: 8053556Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.Type: GrantFiled: August 8, 2006Date of Patent: November 8, 2011Assignee: Oncotherapy Science, Inc.Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Hiroyuki Komori
-
Patent number: 8053557Abstract: It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.Type: GrantFiled: June 15, 2007Date of Patent: November 8, 2011Assignee: Onco Therapy Science, Inc.Inventors: Yasuharu Nishimura, Yoshiaki Ikuta, Shuichi Nakatsuru
-
Publication number: 20110262471Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.Type: ApplicationFiled: October 15, 2009Publication date: October 27, 2011Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
-
Patent number: 8017345Abstract: The object of the present invention is to find out another tumor marker which is useful for early diagnosis of melanoma, and provide a diagnostic kit and diagnostic method for malignant melanoma using such marker. The present invention provides a diagnostic kit for malignant melanoma, which comprises an antibody against SPARC and an antibody against GPC3.Type: GrantFiled: August 9, 2005Date of Patent: September 13, 2011Assignee: Kumamoto UniversityInventors: Yasuharu Nishimura, Tetsuya Nakatsura, Yoshiaki Ikuta